Review
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Nov 26, 2015; 7(11): 719-741
Published online Nov 26, 2015. doi: 10.4330/wjc.v7.i11.719
Vascular endothelial dysfunction and pharmacological treatment
Jin Bo Su
Jin Bo Su, INSERM U955, 94700 Maisons-Alfort, France
Jin Bo Su, Université Paris-Est Créteil Val-de-Marne, 94700 Créteil, France
Author contributions: Su JB wrote the paper.
Conflict-of-interest statement: None declared.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jin Bo Su, PhD, INSERM U955, Equipe 3, ENVA, 7 avenue du Général de Gaulle, 94700 Maisons-Alfort, France. jin-bo.su@inserm.fr
Telephone: +33-1-43967386 Fax: +33-1-43967399
Received: May 5, 2015
Peer-review started: May 8, 2015
First decision: June 3, 2015
Revised: July 23, 2015
Accepted: September 16, 2015
Article in press: September 18, 2015
Published online: November 26, 2015
Processing time: 208 Days and 10.2 Hours
Abstract

The endothelium exerts multiple actions involving regulation of vascular permeability and tone, coagulation and fibrinolysis, inflammatory and immunological reactions and cell growth. Alterations of one or more such actions may cause vascular endothelial dysfunction. Different risk factors such as hypercholesterolemia, homocystinemia, hyperglycemia, hypertension, smoking, inflammation, and aging contribute to the development of endothelial dysfunction. Mechanisms underlying endothelial dysfunction are multiple, including impaired endothelium-derived vasodilators, enhanced endothelium-derived vasoconstrictors, over production of reactive oxygen species and reactive nitrogen species, activation of inflammatory and immune reactions, and imbalance of coagulation and fibrinolysis. Endothelial dysfunction occurs in many cardiovascular diseases, which involves different mechanisms, depending on specific risk factors affecting the disease. Among these mechanisms, a reduction in nitric oxide (NO) bioavailability plays a central role in the development of endothelial dysfunction because NO exerts diverse physiological actions, including vasodilation, anti-inflammation, antiplatelet, antiproliferation and antimigration. Experimental and clinical studies have demonstrated that a variety of currently used or investigational drugs, such as angiotensin-converting enzyme inhibitors, angiotensin AT1 receptors blockers, angiotensin-(1-7), antioxidants, beta-blockers, calcium channel blockers, endothelial NO synthase enhancers, phosphodiesterase 5 inhibitors, sphingosine-1-phosphate and statins, exert endothelial protective effects. Due to the difference in mechanisms of action, these drugs need to be used according to specific mechanisms underlying endothelial dysfunction of the disease.

Keywords: Endothelial dysfunction; Endothelium-dependent vasodilation; Endothelial nitric oxide synthase; Inflammation; Nitric oxide; Pharmacological treatment; Reactive nitrogen species; Reactive oxygen species; Risk factors

Core tip: The endothelium is involved in the regulation of vascular tone and permeability, coagulation and fibrinolysis, inflammatory and immunological reactions and cell growth. Cardiovascular risk factors cause vascular endothelial dysfunction through impairing endothelium-derived vasodilators, enhancing endothelium-derived vasoconstrictors, producing reactive oxygen species and reactive nitrogen species, activating inflammatory and immune reactions and promoting thrombosis. Among these mechanisms, a reduction in nitric oxide bioavailability plays a central role in the development and progression of endothelial dysfunction. A variety of currently used or investigational drugs exert endothelial protective effects according to specific mechanisms underlying endothelial dysfunction of the disease.